How India Exports Lapatinib to the World

In the United States, lapatinib received initial FDA approval under the brand name Tykerb in March 2007. Subsequently, the FDA approved generic versions of lapatinib ditosylate tablets. Notably, Natco Pharma Ltd., a leading Indian exporter, secured FDA approval for its generic lapatinib on September 29, 2020, while Teva Pharmaceuticals USA, Inc. received approval on August 16, 2024. These approvals are documented in the FDA's Orange Book. The presence of multiple approved Abbreviated New Drug Applications (ANDAs) indicates a competitive market landscape. Given that 54.4% of India's lapatinib exports are directed to the United States, the regulatory environment is crucial for Indian exporters. Compliance with FDA regulations, including Good Manufacturing Practices (GMP) and periodic inspections, is essential to maintain market access.

In the European Union, the European Medicines Agency (EMA) granted marketing authorization for lapatinib under the brand name Tyverb in June 2008. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has similarly approved lapatinib for clinical use. Manufacturers exporting to these regions must adhere to stringent EU GMP requirements, which encompass quality assurance, personnel training, and facility standards. Regular inspections by EMA and MHRA ensure compliance. While the EU and UK are not among the top five destinations for India's lapatinib exports, maintaining regulatory compliance is vital for market expansion.

As of the 24th edition of the WHO Model List of Essential Medicines, published in September 2025, lapatinib is not included. The WHO Model List serves as a guide for countries to develop their national essential medicines lists, focusing on medicines that address priority health needs. The absence of lapatinib from this list may influence its adoption in national formularies, particularly in low- and middle-income countries. However, lapatinib is recognized in major pharmacopoeias, including the United States Pharmacopeia (USP) and the British Pharmacopoeia (BP), ensuring standardized quality benchmarks for its production and quality control.

In India, lapatinib is classified under Schedule H of the Drugs and Cosmetics Rules, indicating that it is a prescription-only medication. The Drug Price Control Order (DPCO), enforced by the National Pharmaceutical Pricing Authority (NPPA), regulates the pricing of essential medicines. As of March 2026, lapatinib is not listed under the DPCO, allowing manufacturers to set prices based on market dynamics. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) to ensure that domestic supply is not adversely affected. Compliance with these regulations is imperative for Indian exporters to maintain both domestic and international market access.

The patent landscape for lapatinib has evolved over the years. In August 2013, India's Intellectual Property Appellate Board revoked the patent for GlaxoSmithKline's Tykerb, citing its derivative status, while upholding the original patent for lapatinib. This decision paved the way for generic manufacturers in India to produce and export lapatinib, leading to increased competition and potentially lower prices in global markets.

In April 2025, the World Health Organization unveiled a global repository for National Essential Medicines Lists (nEMLs), providing a centralized digital platform that compiles 150 national essential medicines lists from six global regions. This repository aims to enhance access to critical healthcare data, supporting policymakers, healthcare professionals, and researchers. While lapatinib is not included in the WHO Model List of Essential Medicines, its presence in various national lists could influence its global accessibility and adoption. (who.int)

In January 2026, the FDA updated its list of approved generic drugs, confirming the availability of generic lapatinib ditosylate tablets from multiple manufacturers, including those based in India. This development underscores the increasing competition in the U.S. market and the importance of maintaining stringent quality standards to ensure market share.

In February 2026, the WHO published a fact sheet on essential medicines, emphasizing the need for medicines that effectively and safely treat the priority healthcare needs of populations. The document highlights the importance of medicines being available, affordable, and of assured quality at all times. While lapatinib is not listed in the WHO Model List, its role in treating HER2-positive breast cancer remains significant. (who.int)

In March 2026, the WHO updated its list of National Regulatory Authorities (NRAs) operating at maturity levels 3 and 4, indicating robust regulatory systems. This update is crucial for exporters, as partnering with countries having mature regulatory systems can facilitate smoother market entry and compliance. (who.int)

In March 2026, the WHO published a report on the selection and use of essential medicines, providing updated guidance on the inclusion criteria and processes for the WHO Model List. This report serves as a valuable resource for manufacturers and policymakers in understanding global standards and expectations. (who.int)

These developments highlight the dynamic nature of the pharmaceutical regulatory landscape and underscore the importance for Indian exporters of lapatinib to stay informed and compliant with international standards and regulations.

Lapatinib, an antineoplastic agent, is primarily manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) heavily relies on Key Starting Materials (KSMs) sourced from China. This dependency is part of a broader trend where China controls approximately 70–80% of the global KSM supply and 60–70% of the global intermediate supply, making it a dominant player in the pharmaceutical raw material market.

The reliance on Chinese KSMs introduces significant supply chain vulnerabilities. For instance, environmental regulations in China have led to the shutdown of numerous chemical manufacturing facilities, disrupting the availability of essential raw materials. Such disruptions have previously impacted Indian pharmaceutical manufacturers, leading to increased production costs and potential delays in API availability.

Our proprietary trade data indicates a high supplier concentration for Lapatinib exports from India. The top five exporters account for 92.8% of the total export value, with NATCO PHARMA LIMITED alone contributing 55.4%. This concentration poses a significant single-source risk, as any operational or regulatory issues affecting these key suppliers could disrupt the global supply of Lapatinib.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme aimed at boosting domestic production of critical APIs and reducing dependence on imports. As of November 2024, two greenfield plants were inaugurated under this scheme to manufacture essential molecules like Penicillin G and 6-APA, marking a significant step towards self-reliance in pharmaceutical manufacturing.

Recent geopolitical tensions have further exacerbated supply chain risks. In February 2026, military conflicts in the Middle East led to the effective closure of the Strait of Hormuz, a critical maritime chokepoint. This disruption has significantly impacted the global shipping industry, causing delays and increased costs for goods transiting through this route.

Additionally, the U.S. Food and Drug Administration (FDA) has reported drug shortages due to various factors, including manufacturing and quality problems, delays, and discontinuations. While Lapatinib is not currently listed as in shortage, the existing supply chain vulnerabilities highlight the potential for future disruptions.

• Diversify KSM Sourcing: Identify and develop alternative suppliers for KSMs beyond China to reduce dependency and mitigate risks associated with supply disruptions.

• Enhance Domestic Production: Leverage government initiatives like the PLI scheme to bolster domestic manufacturing capabilities for both APIs and KSMs, thereby reducing reliance on imports.

• Strengthen Supplier Relationships: Establish strategic partnerships with multiple suppliers to ensure a more resilient supply chain and reduce single-source dependency.

• Monitor Geopolitical Developments: Implement a robust monitoring system to stay informed about geopolitical events that could impact supply chains, allowing for proactive risk management.

• Invest in Supply Chain Transparency: Utilize advanced tracking and reporting systems to gain real-time visibility into the supply chain, enabling swift responses to potential disruptions.

RISK_LEVEL: HIGH